Business
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Oral mucositis, also called \"chemo mouth,\" has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task forceUp to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\") today announced that Jaguar family company Napo Pharmaceuticals (Napo) is exhibiting Gelclair ® , the FDA-approved oral mucositis prescription product, at the American Society for Radiation Oncology (ASTRO) Annual Meeting , which takes place September 29 - October 2, 2024 in Washington, DC. Jaguar plans to begin the U.S. commercial launch in October 2024 for Gelclair.\"Oral mucositis is among the most common, painful, and debilitating cancer treatment-related side effects. Gelclair is a protective gel with a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis. Unlike other products for oral mucositis, it is not a numbing agent and does not sting the mouth,\" said Lisa Conte, Jaguar's president and CEO. \"We look forward to driving awareness among oncologists at the ASTRO Annual Meeting about Gelclair and Jaguar's expanding focus on cancer supportive care.\"Oral mucositis, also called \"chemo mouth,\" has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network (NCCN) task force. 1 Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy. 2 Of the latter, 19% may end up being hospitalized, experiencing a delay in antineoplastic treatment for high-grade mucositis management, resulting in a reduction of the quality of life, a worse prognosis, and an increase in patient management costs. 2 Oral mucositis can negatively affect diet, nutrition, oral hygiene, as well as quality of life. 3 Its adverse physical, social and psychological impacts on patients are manifest and include the need for total parenteral nutrition, ...